Isothermal Nucleic Acid Amplification Technology Market Segmented by Product Type - Instruments | Reagent
Industry: Healthcare
Published Date: November-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 342
Report ID: PMRREP33206
The global market for isothermal nucleic acid amplification technology was estimated to be worth US$ 4.2 Billion in 2022, and it is expected to increase at a splendid CAGR of 12% over the next ten years. Due to the increased incidence of infectious illnesses, the adoption of technology is booming as a reliable molecular diagnostic method and is expected to make the overall market value reach US$ 13 Billion by the end of the forecast period in the year 2032.
The market is anticipated to rise as a result of growing concerns about antibiotic resistance and increased attention to the mitigation of contagious diseases outbreak in developing nations. Furthermore, by checking transfused blood serum for the mere existence of any potential pathogens, the use of isothermal nucleic acid amplification technology in this situation is growing exponentially in present times.
|
Attributes |
Details |
|
Isothermal Nucleic Acid Amplification Technology Market CAGR (2022 to 2032) |
12% |
|
Isothermal Nucleic Acid Amplification Technology Market Size (2022) |
US$ 4.2 Billion |
|
Isothermal Nucleic Acid Amplification Technology Market (2032) |
US$ 13 Billion |
The widely available option of point-of-care applications for conventional amplification technologies like PCR is constrained by the scarcity of apparatus capable of heat cycling and thermal management. So isothermal amplification technologies for molecular diagnostics benefit greatly from this since they have a reduced energy need and allow for test incubation in any portable battery-powered system.
The outbreak of the Covid-19 epidemic has boosted demand for quick and precise test options meant to detect the SARS-CoV-2 virus, which has boosted the market opportunities immensely. The USFDA had also granted emergency use authorization for fresh INAAT-based COVID-19 testing toolkits that many significant companies had created. In fact, the Procleix SARS-CoV-2 assay from Grifols Diagnostic Solutions Inc. and the Lucira CHECK-IT COVID-19 test kit from Lucira Health Inc. are now widely available technologies in the market. These tactical moves, motivated by the speculation of any such future event, are probably going to strengthen the market's key trends and opportunities.
Increasing financing from different government organizations, as well as private healthcare organizations, rapid analytic tools are being adopted more widely to help fight infectious illnesses, thanks in part to CDC and NIH initiatives. Similarly, the isothermal nucleic acid amplification technology industry expansion is anticipated to be aided by growing capacity and automation provided by such technologies for the processing and handling of numerous samples within a short period of time.
The sales of INAAT instruments in the global market are rising as a result of increased R&D contribution in the creation of innovative diagnostics for novel contagious diseases like COVID-19. Similarly, upgraded diagnostic devices with improved reliability, mobility, and efficiency might significantly improve the market structure for INAAT equipment employed in communicable disease control and management.
Additionally, it is anticipated that isothermal nucleic acid amplification technology diagnostics would increase in market penetration in the near future with improving healthcare infrastructure. This growth would be supported by the increase in production of the associated reagents over the course of the projected timeframe.
Unfortunately, the legal framework guiding the establishment and progress of INAAT-based diagnostics and treatment methods is a significant barrier restricting the market's potential. Secondly, the marketing of INAAT solutions are constrained due to low awareness among patients and ambiguous laws for INAAT-based diagnostics.
Additionally, the lack of a strong compensation mechanism in industrialized countries like the United States can severely restrict consumers' purchasing power. These elements may limit market expansion throughout the anticipated time frame.
The market share held by loop-mediated isothermal amplification or LAMP in 2021 was figured out to be nearly 16% as this technique supports a variety of detection methods, including the Zika virus and the SARS-CoV-2 virus as well as real-time fluorescence employing intercalators. It may therefore continue to remain the highest contributing segment through the forecast years.
Some of the other technology segments that had a major impact on the studied market through the past few years were transcription-mediated amplification, or TMA, as well as helicase-dependent amplification, or HDA.
What is the Major Application of the Isothermal Nucleic Acid Amplification Technology?
As per the market analysis report, the applications segment for diagnosing infectious diseases held the predominant share, with 35% of the overall market revenue generated in the year 2021. The important drivers that are expected to drive the growth of this category include the recent development of particular INAAT kits and the rising prevalence of HIV, hepatitis A and B, and several sexually transmitted illnesses.
Owing to the ever-increasing need for blood screening and analysis due to the increasing amount of blood donation and transfusions throughout the world, this segment has turned out to be an essential application of isothermal amplification techniques these days.
Which are the Prominent End-users for the Isothermal Nucleic Acid Amplification Technology Market Players?
Based on end users, the hospitals or healthcare centers segment had the greatest market share at about 40%. This seems to be due to the creation of miniature point-of-care INAAT equipment, which allows for single-level access enabling hospital-based analysis to be more acceptable.
Due to the growing usage of molecular diagnostic methods in medical laboratories and the increased prevalence of reference laboratories, the market sector for central and reference laboratories end-use segments are anticipated to rise significantly over the course of the forecast period. Owing to its intensifying use in clinics, hospitals, and other primary healthcare facilities, as well as the growing accessibility of polymerases featuring great reverse transcription capabilities, the reagents product segment contributed profoundly to the studied market in the years until 2021.
|
Attributes |
Isothermal Nucleic Acid Amplification Technology Market |
|
CAGR (2022 to 2032) |
12% |
|
Market Value (2022) |
US$ 4.2 Billion |
|
Growth Factor |
The rising prevalence of chronic illnesses and an aging population around the world has increased the demand for precise and efficient diagnostic technologies. |
|
Future Opportunities |
An improvement in the usage of INAAT over PCR, and a rise in demand for affordable and efficient diagnostics techniques is anticipated to surge the demand further. |
|
Market Trends |
The LAMP section is most expected to increase in line with the demand for point-of-care diagnostic services and businesses. |
|
Attributes |
Oncology based Molecular Diagnostics Market |
|
CAGR (2022 to 2032) |
14% |
|
Market Value (2022) |
US$ 3.4 Billion |
|
Growth Factor |
Breast, colorectal, and non-small cell lung cancer (NSCLC) are becoming more and more common among the global population increasing the adoption of the method. |
|
Future Opportunities |
Increased patient and healthcare professional knowledge of early cancer diagnosis and distinction would increase the use of molecular diagnostics. |
|
Market Trends |
The rising demand for technologically enhanced diagnostics solutions on the basis of accuracy, speed, and cost-effectiveness. |
|
Attributes |
Epigenetics Drugs and Diagnostic Technologies Market |
|
CAGR (2022 to 2032) |
19.5% |
|
Market Value (2022) |
US$ 12.5 Billion |
|
Growth Factor |
Numerous reasons, including the expanding elderly population and the higher incidence of cancer and several other chronic illnesses in all major economies. |
|
Future Opportunities |
Launching new products and probable future commercialization of items that are presently in development is likely to boost the overall demand. |
|
Market Trends |
R&D initiatives for the growing need to comprehend molecular-level epigenetic changes and the creation of therapeutic remedies. |
Why the United States is the Leading Region in Global Isothermal Nucleic Acid Amplification Technology Market Growth?
As evident from the market survey report, the United States contributed almost 40% of the revenue generated globally.
Due to its developed research network with robust healthcare infrastructure and rising demand for nucleic acid amplification-based treatments, the United States held the biggest market share until the year 2021. Additionally, it is projected that high per capita healthcare spending and rising interest in point-of-care diagnostic techniques may propel the isothermal nucleic acid amplification technology business expansion further.
What are the Growth Opportunities for Isothermal Nucleic Acid Amplification Technology in European Countries?
Due to the prevalence of chronic illnesses and the growing preference for isothermal amplification technology over traditional methods in the area, Europe now has a dominant position in the INAAT market.
As per the market survey report for the previous years, Germany's INAAT market had a very noticeable share because of the nation's aging population and intense attention to its healthcare systems. The World Bank predicted that in 2021, the country's population over 65 years old will make up 22% of contributing to a significant predominance of age-related illnesses, which may improve the future market prospects for efficient INAAT devices.
How Japan Lucrative Isothermal Nucleic Acid Amplification Technology Market Share is growing?
Asia Pacific is projected to be a rapidly growing market for isothermal nucleic acid amplification technology in the coming days, and Japan is anticipated to be a lucrative market during the forecast period.
However, there are major issues that need to be taken care of by the domestic players to compete in the global market. For instance, the manufacture of INAAT devices is more difficult since regulatory organizations like the PMDA in Japan have strict rules for evaluating their manufacturing operations.
As a result of the top competitors' deployment of significant strategic efforts, the global isothermal nucleic acid amplification technology market is getting extremely competitive day by day. Mostly during the projection time span, it is predicted that intense competition between major companies, namely Hologic, Inc., which provides TMA technologies, and Quidel Corporation, which provides HDA product lines, would be instrumental in propelling a stable growth of the said market.
For instance, the novel Lyo-Ready Direct RNA/DNA LAMP and Lyo-Ready Direct DNA LAMP Saliva Mix master mixes for isothermal amplification technologies were introduced by Meridian Bioscience, Inc. in May 2022.
|
Attributes |
Details |
|
Forecast Period |
2022 to 2032 |
|
Historical Data Available For |
2017 to 2021 |
|
Market Analysis |
US$ Million for Value |
|
Key Countries Covered |
|
|
By Market Segments |
|
|
Key Companies Profiled |
|
|
Pricing |
Available Upon Request |
Isothermal Nucleic Acid Amplification Technology Industry by Product Type
Isothermal Nucleic Acid Amplification Technology Market by Technology
Isothermal Nucleic Acid Amplification Technology by Application
Isothermal Nucleic Acid Amplification Technology Market by End User
Isothermal Nucleic Acid Amplification Technology Market by Region
To know more about delivery timeline for this report Contact Sales
The global isothermal nucleic acid amplification technology market was estimated at US$ 4.2 Billion in 2022.
The global isothermal nucleic acid amplification technology market likely grow at a rate of 12% through 2032.
The global isothermal nucleic acid amplification technology market is expected to garner US$ 13 Billion by 2032.
The US is projected to be the best performing regional isothermal nucleic acid amplification technology market.
The LAMP segment is expected to take a lead while recording a 16% share.
